Recruiting Alzheimers Disease Studies in Chapel Hill
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Recurrent/Metastatic Head and Neck Cancer
The purpose of this study is to determine safety and preliminary efficacy of amivantamab monotherapy, amivantamab in addition to pembrolizumab, amivantamab in addition to paclitaxel and amivantamab in...
A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies
This study is researching an experimental drug called REGN10597 (called "study drug"). The study is focused on patients with certain solid tumors that are in an advanced stage. The aim of the study i...
Pembrolizumab Plus Olaparib in LA-HNSCC
The purpose of this research study is to evaluate the effectiveness of using a combination of pembrolizumab and olaparib when given before and after standard chemoradiation therapy in treating locally...
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa
The purpose of the study is to assess the PK of bimekizumab following subcutaneous (sc) administration in study participants with moderate to severe hidradenitis suppurativa (HS)...
About Alzheimers Disease Clinical Trials in Chapel Hill
Alzheimer's disease is a progressive brain disorder that destroys memory, thinking skills, and the ability to carry out daily tasks. It is the most common cause of dementia, affecting over 6.7 million Americans age 65 and older. The disease is characterized by amyloid-beta plaques and tau tangles in the brain. Recent FDA approvals of anti-amyloid antibodies like lecanemab (Leqembi) and donanemab have opened a new era of disease-modifying treatments. Clinical trials are now exploring next-generation amyloid-clearing therapies, tau-targeting treatments, anti-inflammatory approaches, and combination strategies. Early-stage patients with mild cognitive impairment or early Alzheimer's are frequently sought for enrollment, and many trials now use blood-based biomarkers for screening.
There are currently 4 alzheimers disease clinical trials recruiting participants in Chapel Hill, NC. These studies are seeking a combined 482 participants. Research is being sponsored by Janssen Research & Development, LLC, Regeneron Pharmaceuticals, UNC Lineberger Comprehensive Cancer Center and 1 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Alzheimers Disease Clinical Trials in Chapel Hill — FAQ
Are there alzheimers disease clinical trials in Chapel Hill?
Yes, there are 4 alzheimers disease clinical trials currently recruiting in Chapel Hill, NC. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Chapel Hill?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Chapel Hill research site will contact you about next steps.
Are clinical trials in Chapel Hill free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Chapel Hill studies also compensate for your time and travel.
What alzheimers disease treatments are being tested?
The 4 active trials in Chapel Hill are testing new therapies including novel drugs, biologics, and treatment approaches for alzheimers disease.
Data updated March 2, 2026 from ClinicalTrials.gov